Search
Copyright © 2025 ALM Global, LLC. All Rights Reserved.
Robert F. Kennedy Jr. testified Thursday in Washington at a nomination hearing conducted by the Senate Health, Education, Labor and Pensions Committee. Credit: Senate HELP Robert F. Kennedy Jr. said he believes in careful use of the GLP-1 agonist anti-obesity drugs to help people coping with morbid obesity or diabetes.
President Donald Trump has nominated Kennedy to be the secretary of the U.S. Department of Health and Human Services, which oversees the U.S. Food and Drug Administration, Medicare and Medicaid and helps enforce the Affordable Care Act commercial health insurance rules.
NOT FOR REPRINT
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
eBook
Sponsored by Nova Healthcare Administrators, Inc.
Client Clarity: Breaking Down Your Health Plan Needs
Guiding your clients to the right network solution is vital for balancing costs, access, and employee satisfaction. Use this eBook as a strategic and educational tool to provide clarity for your clients around the ins and outs of network solutions.
White Paper
Sponsored by Noom Health
As obesity rates rise, GLP-1 medications are gaining popularity. Yet, the multifactorial obesity epidemic presents challenges for organizations as more employees seek GLP-1’s. This white paper explores actionable strategies to help cut costs, improve employee health outcomes, and achieve a measurable ROI.
Report
Sponsored by New Benefits
This report reveals the top non-insured benefits that not only reduce costs but also address the rising challenges of burnout, financial stress, and work-life balance. Give your clients the edge they need to support their employees while driving business growth. Download the report now to learn more!
Copyright © 2025 ALM Global, LLC. All Rights Reserved.
Sign In
Sign In
